Related Experiment Video
Updated: Jan 3, 2026
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound
Paul A Allegretti1, Timothy M Horton2, Yassan Abdolazimi3
1Department of Medicine and Division of Endocrinology, Stanford University, Stanford, CA 94305, USA; Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA.
Abstract:
Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replication, current lead compounds have inadequate cellular potency for in vivo application. Herein, we report the clinical stage anti-cancer kinase inhibitor OTS167 as a structurally novel, remarkably potent DYRK1A inhibitor and inducer of human β-cell replication. Unfortunately, OTS167's target promiscuity and cytotoxicity curtails utility. To tailor kinase selectivity towards DYRK1A and reduce cytotoxicity we designed a library of fifty-one OTS167 derivatives based upon a modeled structure of the DYRK1A-OTS167 complex. Indeed, derivative characterization yielded several leads with exceptional DYRK1A inhibition and human β-cell replication promoting potencies but substantially reduced cytotoxicity. These compounds are the most potent human β-cell replication-promoting compounds yet described and exemplify the potential to purposefully leverage off-target activities of advanced stage compounds for a desired application.
Insights
Researchers developed new compounds to stimulate beta-cell regeneration for diabetes treatment. These potent DYRK1A inhibitors promote human beta-cell replication with reduced toxicity, offering a promising therapeutic avenue.
Area of Science:
- Endocrinology
- Molecular Biology
- Drug Discovery
Background:
- Diabetes mellitus treatment strategies include stimulating pancreatic beta-cell regeneration.
- Inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) enhances beta-cell replication.
- Existing DYRK1A inhibitors lack sufficient potency for in vivo application.
Purpose of the Study:
- To identify potent and selective DYRK1A inhibitors for therapeutic beta-cell regeneration.
- To develop novel compounds based on the anti-cancer drug OTS167 with improved selectivity and reduced cytotoxicity.
Main Methods:
- Designed and synthesized a library of 51 OTS167 derivatives.
- Utilized a modeled structure of the DYRK1A-OTS167 complex for rational drug design.
- Evaluated compound potency for DYRK1A inhibition and human beta-cell replication, alongside cytotoxicity assessments.
Main Results:
- Identified novel OTS167 derivatives with potent DYRK1A inhibition.
- Demonstrated significant induction of human beta-cell replication by the novel compounds.
- Achieved substantially reduced cytotoxicity compared to the parent compound, OTS167.
Conclusions:
- Developed highly potent inducers of human beta-cell replication with improved DYRK1A selectivity.
- These compounds represent the most potent beta-cell replication promoters described to date.
- Highlights the potential of repurposing advanced-stage compounds by targeting specific kinase activities.
